CROWN POINT, Ind. — OYE Therapeutics Inc. , a clinical-stage biotechnology company developing therapies for perioperative and emergency medicine, announced that the first subject has been dosed in its scientific bridging study evaluating OYE-101.
The novel intravenous caffeine formulation is designed to accelerate recovery from general anesthesia and deep sedation.
“OYE-101 is designed to address an important gap in perioperative and acute-care medicine,” said Brett Dines, CEO of OYE Therapeutics. “Advancing the program into the clinic allows us to begin generating human clinical data through a scientific bridging study designed to support a 505(b)(2) NDA (new drug application) for a formulation intended to enable faster and more predictable recovery from anesthesia and deep sedation.”
OYE operates from the Purdue Technology Center in the Purdue Research Park of Northwest Indiana .
General anesthesia and deep sedation are used in millions of surgical and procedural cases annually. Delayed emergence, residual sedation and respiratory complications remain significant contributors to extended recovery time and hospital resource utilization.
OYE-101 is being developed as a pharmacologic approach intended to support faster and more predictable emergence from anesthesia while maintaining patient safety, an area where no FDA-approved drugs are currently indicated to actively promote recovery from general anesthesia.
About OYE Therapeutics
OYE Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies that improve outcomes in surgical, emergency and acute-care medicine. The company’s lead program, OYE-101, is a novel intravenous caffeine formulation designed to accelerate recovery from anesthesia and deep sedation and to address related respiratory complications. OYE Therapeutics is headquartered at the Purdue Technology Center in Crown Point, Indiana.
Media contact: Michael Hicks, OYE Therapeutics, Chief Operating Officer, mhicks@oyetherapeutics.com , 219-281-2369